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yearswere employable and actually employed, respectively. AverageHAQ scores at
week 24 were 1.08 and 0.92 for MTX and GLM, respectively. Among patients ‘un-
employable’ at baseline, 33% of GLM and 15% of MTX patients became employable
at wk24 (p0.04). GLM-treated patients maintained HAQ improvement through
wk160 (mean score0.88). In logistic regressionmodeling, for patients with amean
age of 50 years, expected EALYs were 5.92 and 7.15 for female and male GLM-
treated patients, compared with 4.96 and 6.28 for female and male MTX-treated
patients, an increase of 0.96 (19.2%) and 0.87 (13.8%) EALYs in GLM-treated females
and males. Sensitivity analysis demonstrated improvements of 0.81 (16.4%) and
0.74 (11.8%) ELAYs in male and female GLM-treated patients relative to MTX-
treated patients. CONCLUSIONS: Results of EALY analysis indicated GLMMTX-
treated RA patients can realize improvement in employability over time.
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OBJECTIVES: Rheumatoid Arthritis (RA) patient registries that follow up patients
who are on anti-TNFmedication provide a rich source of data to evaluate costs and
effectiveness of these treatments in real world practice. The study aims to assess
the impact of anti-TNF as compared with standard DMARDs on healthcare utiliza-
tion and costs in an inception patient cohort with RA in Alberta. METHODS: The
Alberta Rheumatoid Arthritis Biologics Study Database includes patients treated
with either standard DMARDs or one of three available anti-TNFs and followed for
up to 3 years. Provincial administrative databases between 1.4.2004 and 31.3.2009
were analyzed to identify physician visits, emergency room (ER) and other ambu-
latory visits, hospitalizations, and costs. A propensity score matching technique
was used to compare these outcomes in the first anti-TNF-only to DMARD-only,
DMARD switch to anti-TNF, or anti-TNF switch to another anti-TNF groups, and
bootstrapmethodwas used to estimate 95% confidence intervals of the differences.
2008 Alberta costs of health services were used for analysis. RESULTS: Of 1,222
patients in the database, 1,087 had at least 3 months of administrative data. The
average annual number of visits and costs for the first anti-TNF-only groupwere for
physician services (19.1; $1,568), emergency room (6.7; $1,378), and hospitalizations
(0.22; $1,983), with the total annual per patient cost being $4,929. Compared to this
group, the costs and utilizations in the anti-TNF switching to another anti-TNF
were significantly higher (except hospital costs). However, the DMARD groups’
higher utilization and cost estimates were not statistically significant.
CONCLUSIONS: Staying on the first anti-TNF reduces significantly the utilization
and cost of health services compared to patients switching anti-TNF medication.
Due to small samples the comparison to patients starting DMARD medication did
not show significant differences.
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OBJECTIVES: To examine adoption, choice, and utilization of rheumatoid arthritis
(RA) biologic therapies and the patient and plan characteristics associated with
these in Medicare. METHODS: Nationally representative 2006–2008 5% Medicare
Parts A, B, and D files were examined. The sample (N47,511) consisted of pooled
annual cross-sections of fee-for-service beneficiaries with Part D coverage and 1
inpatient or 2 outpatient claims with RA diagnosis (ICD-9-CM 714.xx). Logistic re-
gressions with robust clustered standard errors were estimated to identify patient
and plan characteristics associated with any biologics use, biologics use under Part
B (i.e. physician administered infusion) versus Part D (i.e. self-injectable), anduse of
specific biologics under Part D. RESULTS: From 2006 to 2008, RA biologics use de-
creased slightly (15.0% to 14.0%). The proportion of biologic users utilizing Part D
biologics decreased from 60% to 50%. Disabled or female RA patients were more
likely (OR1.3, 95% CI 1.2-1.5, for both) to use biologics; older patients were less
likely (OR0.5, 95%CI .4-0.5). RA patients in the South were more likely to use
biologics relative to the Northeast (OR1.3, 95% CI 1.2-1.5). Among RA biologic
users, patients in the Midwest (OR0.5, 95% CI 0.4-0.7) or South (OR0.6, 95% CI
0.5-0.8) were less likely to use Part D biologics relative to the Northeast. Patients
qualifying for Part D low-income subsidies (LIS) with minimal Part D cost-sharing
weremore likely to use Part D biologics compared to non-LIS patients (OR2.6, 95%
CI 1.8-3.8). Furthermore, non-LIS RA patients were more likely to use adalimumab
(OR1.5, 95% CI 1.1-2.1) if they were enrolled in plans that had more utilization
management tools for etanercept; however, a similar effect was not noted in LIS
patients. CONCLUSIONS: Strong geographic variation exists in utilization of RA
biologics in Medicare. Part D cost-sharing and utilization management tools also
influence choice of biologics.
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OBJECTIVES: The objective of this study is to compare prevalence of treatment for
osteoporosis and identify predictors for osteoporosis treatment in elderly women
residing in the community and in long-term care facilities. METHODS: This is a
cross-sectional study using Medicare beneficiaries participating in the Medicare
Current Beneficiary Survey (MCBS) between 2000 and 2003. The study population
was femaleMedicare beneficiaries aged 65 and olderwith evidence of osteoporosis.
The outcome variable captured drugs used to treat osteoporosis, including bispho-
sphonates, calcitonin, estrogens, parathyroid hormone analog and selective estro-
gen receptormodulator (SERM). The covariate of interestwas an indicator of type of
residence (i.e. commumity or long-term care facility) identified from survey data.
RESULTS: The final study sample included 4,221 community dwellers and 394
facility residents with evidence of osteoporosis. The unadjusted prevalence of os-
teoporoses treatment was 52.1% for community dwellers and 40.9% for facility
residents. However, after adjusting for other covariates, the adjusted prevalence of
treatment was 52.0% (95% CI[51.6%, 52.5%]) for community dwellers and 65.3%
(95% CI[64.9%, 65.7%]) for facility residents. The main factors that caused the flip
in adjusted prevalence of treatment were age and limitations in activities of daily
living (ADLs). Compared to patients aged 65-74, patients aged 75 and older were
significantly less likely to be treated (AOR0.81, 95% CI[0.69,0.95] for age 75-84
and AOR0.54, 95% CI[0.44, 0.67] for age 85 and older). Each additional ADL re-
duced to odds of treatment by AOR0.87, 95% CI[0.64, 0.91]. CONCLUSIONS: The
lower prevalence of osteoporoses treatment observed among community dwellers
compared to facility residents is mainly due to differences in age and ADL limita-
tions. For elderlywomenwith the same characteristics, residents in long-term care
facilities were actually more likely to receive osteoporosis treatment compared to
their community counterparts over the study period.
PMS51
RACIAL DISPARITIES IN UTILIZATION OF BIOLOGIC AND DISEASE-MODIFYING
ANTI-RHEUMATIC DRUGS IN A CALIFORNIA MEDICAID POPULATION WITH
RHEUMATOID ARTHRITIS
Nichol MB1, Wu J1, Harker JO2, Knight TK1, Wong AL3
1University of Southern California, Los Angeles, CA, USA, 2Olive View-UCLA Education and
Research Institute, Sylmar, CA, USA, 3Olive View-UCLA Medical Center, Sylmar, CA, USA
OBJECTIVES: 1) To investigate racial disparities in medication use in Rheumatoid
Arthritis (RA) patients; 2) To identify factors associated with using a biologic tumor
necrosis factor inhibitor (biologic-TNF). METHODS: We identified patients 18-64
years old with at least two diagnoses of RA and one prescription fill for Disease-
Modifying Anti-Rheumatic Drugs (DMARDs) within the first year of diagnosis from
the California Medicaid (Medi-Cal) claims data (1995-2006). The annual prevalence
of medication use for each racial group was calculated. A generalized linear model
was used to assess for predictors of annual biologic-TNF use during 1999-2006.
RESULTS:We analyzed 6,463 patients. The biologic-TNF use increased from 7.0%,
6.5%, 2.5% in 1999 to 22.9%, 24.5%, and 14.3% in 2006; but the DMARD use decreased
from 80.7%, 82.3%, 76.8% in 1995 to 71.9%, 72.4%, and 71.4% in 1999 for Whites,
Hispanics, and Blacks, respectively (all p0.0001). The difference in prevalence of
biologic-TNF use between Whites and Blacks ranged from 4.5% in 1999 to 11.0% in
2005. The DMARD use among racial groups was not different during 1995-2000
(pre-biologic) (all p0.05). Hispanics (75.3% to 81.0%) were more likely to use
DMARDs thanWhites (74.0% to 70.1%) or Blacks (64.0%) to 66.5%) from 2001 to 2006
(all p0.001). The differences in prevalence of DMARD use between Whites and
Blacks were largest (12.4%) in 2002, but decreased to 3.6% in 2006 (all p0.001).
Significant predictors of biologic-TNF use included Blacks [Odd ratio (OR)0.48],
Hispanics (OR0.68) as compared toWhites, Medi-Cal andMedicare dual eligibility
(OR1.34), not filling DMARD (OR0.34), greater number of RA medication fills
(OR2.12), fewer comorbidities (OR0.88), and access to a Rheumatologist
(OR1.01). CONCLUSIONS: Biologic-TNF and DMARDs were used disproportion-
ately in Blacks and Hispanics across 1999 to 2006. In addition to race, clinical/
treatment factors, comorbidity, and Medicare eligibility have significant impact on
utilization of biologic-TNF.
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OBJECTIVES: Bisphosphonates are cornerstone of osteoporosis management as
they are effective in both prevention and treatment of osteoporosis. The objective
of this study is to identify the predictors of bisphosphonate prescription among
patients with osteoporosis.METHODS: All patients 40 years and diagnosed with
osteoporosis (ICD-9-CM: 733.0) were identified from National Ambulatory Medical
Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey
(NHAMCS), 2006-07. Bivariate and multivariate logistic regression was carried out
to identify the predictors of Bisphosphonate prescription. RESULTS: According to
the survey, about 44.4 (CI: 38.8 – 50.8) million visits were made for osteoporosis. Of
the visits, about 14 (CI: 11 – 16.4) million visits involved bisphosphonates. Alendro-
nate (61.5%) and Risedronate (25.29%) were themost commonly prescribed bispho-
sphonates. Multivariate analysis suggested that women (OR: 2.74; C.I.:1.62-4.62)
were more likely to be prescribed bisphosphonates as compared to males. Also
visits made by patients of age  70 (OR: 2.60; C.I.:1.11-6.06) were more likely to be
prescribed bisphosphonates than those between 40-49 years. Race, physician spe-
ciality, metropolitan area and payment type were not associated with bisphospho-
nates prescription. CONCLUSIONS: Bisphosphonates are commonly used in osteo-
porosis management. However drug utilization rates vary with age and gender.
More research is needed to understand the variation in bisphophonate prescribing.
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